ICER Releases Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy Ahead of FDA Approval

November 12, 2021

The Institute for Clinical and Economic Review (ICER) has released its evidence report for mavacamten, used to treat hypertrophic cardiomyopathy (HCM). The drug targets myosin in cardiac muscle to reduce contraction in the heart, thereby reducing cardiac hypertrophy. Reviewers call for a price tag capped at $15,000 per year, lower than the placeholder price of $75,000. The Food and Drug Administration will decide the drug’s fate early next year.

ICER Chief Medical Officer David Rind remarks, “The evidence suggests that mavacamten may deliver important health benefits for patients with a low rate of side effects seen with other medications for HCM, but clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction in some patients.” Read more here.

(Source: ICER, 10/7/21)

Share This Story!